NOVAREX Co.Ltd (194700) - Cash Flow Conversion Efficiency
Based on the latest financial reports, NOVAREX Co.Ltd (194700) has a cash flow conversion efficiency ratio of 0.101x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩25.65 Billion ≈ $17.38 Million USD) by net assets (₩254.64 Billion ≈ $172.57 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
NOVAREX Co.Ltd - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how NOVAREX Co.Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read NOVAREX Co.Ltd balance sheet liabilities for a breakdown of total debt and financial obligations.
NOVAREX Co.Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of NOVAREX Co.Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CHC Healthcare Group
TW:4164
|
0.034x |
|
Dynamix Corporation
NASDAQ:ETHM
|
-0.003x |
|
Vina San Pedro
SN:VSPT
|
0.001x |
|
Parrot
PA:PARRO
|
-0.462x |
|
FineTek Co Ltd
TWO:4549
|
0.008x |
|
Wei Chih Steel Industrial Co Ltd
TW:2028
|
0.114x |
|
TIDEWATER RENEWABLES LTD
F:7GZ
|
-0.003x |
|
Amrutanjan Health Care Limited
NSE:AMRUTANJAN
|
0.032x |
Annual Cash Flow Conversion Efficiency for NOVAREX Co.Ltd (2015–2025)
The table below shows the annual cash flow conversion efficiency of NOVAREX Co.Ltd from 2015 to 2025. For the full company profile with market capitalisation and key ratios, see how much is NOVAREX Co.Ltd worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩254.64 Billion ≈ $172.57 Million |
₩16.65 Billion ≈ $11.28 Million |
0.065x | +8.25% |
| 2024-12-31 | ₩220.26 Billion ≈ $149.27 Million |
₩13.31 Billion ≈ $9.02 Million |
0.060x | -52.15% |
| 2023-12-31 | ₩200.42 Billion ≈ $135.82 Million |
₩25.30 Billion ≈ $17.15 Million |
0.126x | +13.88% |
| 2022-12-31 | ₩181.37 Billion ≈ $122.91 Million |
₩20.11 Billion ≈ $13.63 Million |
0.111x | -35.83% |
| 2021-12-31 | ₩139.67 Billion ≈ $94.65 Million |
₩24.13 Billion ≈ $16.35 Million |
0.173x | +22.84% |
| 2020-12-31 | ₩115.61 Billion ≈ $78.35 Million |
₩16.26 Billion ≈ $11.02 Million |
0.141x | +1093.29% |
| 2019-12-31 | ₩91.79 Billion ≈ $62.21 Million |
₩-1.30 Billion ≈ $-880.82K |
-0.014x | -115.01% |
| 2018-12-31 | ₩78.93 Billion ≈ $53.49 Million |
₩7.44 Billion ≈ $5.04 Million |
0.094x | -53.95% |
| 2017-12-31 | ₩51.88 Billion ≈ $35.16 Million |
₩10.62 Billion ≈ $7.20 Million |
0.205x | +23.86% |
| 2016-12-31 | ₩44.62 Billion ≈ $30.24 Million |
₩7.38 Billion ≈ $5.00 Million |
0.165x | -31.13% |
| 2015-12-31 | ₩36.31 Billion ≈ $24.61 Million |
₩8.72 Billion ≈ $5.91 Million |
0.240x | -- |
About NOVAREX Co.Ltd
NOVAREX Co.,Ltd. manufactures, wholesales, and retails health and functional foods in South Korea and internationally. It offers lactic acid bacteria, omega-3, icle time, eye health, diet, boswellia, and lutein and zeaxanthin, as well as vitamin and mineral products in the form of tablets, soft and hard capsules, powder, liquid, gel, and jellies. The company was formerly known as Health Science C… Read more